Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Theprubicin
Transcatheter Arterial Chemoembolization
Sun Yat-sen UniversityN/AD (30)
Tislelizumab
Anti-PD1/PDL1 Antibody
Sun Yat-sen UniversityD (30)
Tislelizumab
PD-1 Inhibitor
Sun Yat-sen UniversityD (30)
Toripalimab
Anti-PD1/PDL1 Antibody
Sun Yat-sen UniversityD (30)
Toripalimab
Liver Cancer
Sun Yat-sen UniversityD (30)
Toripalimab
Lenvatinib
Sun Yat-sen UniversityD (30)
Toripalimab
PD-1 Inhibitor
Sun Yat-sen UniversityD (30)
Tucidinostat
Adverse Event
Sun Yat-sen UniversityN/AD (30)
Tucidinostat
Complete Remission Rate， CRR
Sun Yat-sen UniversityN/AD (30)
Tucidinostat
Duration of Response
Sun Yat-sen UniversityN/AD (30)
Tucidinostat
Overall Survival
Sun Yat-sen UniversityN/AD (30)
Tucidinostat
Progression Free Survival
Sun Yat-sen UniversityN/AD (30)
(+)-VINCRISTINE
Anti-PD1/PDL1 Antibody
Sun Yat-sen UniversityD (30)
(+)-VINCRISTINE
Cadonilimab
Sun Yat-sen UniversityN/AD (30)
(+)-VINCRISTINE
Cryoablation
Sun Yat-sen UniversityN/AD (30)
(+)-VINCRISTINE
Pulmonary Metastases
Sun Yat-sen UniversityN/AD (30)
Ganglioside-Monosialic Acid
Chemotherapy-Induced Toxicity
Sun Yat-sen UniversityP3NR (0)
Adebelimab
Mucosal Melanoma
Sun Yat-sen UniversityP2NR (0)
Cetuximab Beta
Non-Small Cell Lung Carcinoma
Sun Yat-sen UniversityP2NR (0)
Cetuxima-Β
Colorectal Cancer
Sun Yat-sen UniversityP2/3NR (0)
Showing 451 to 470 of 470 assets
PreviousPage 19 of 19Next